Results 91 to 100 of about 281,748 (215)

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?

Seminars in Immunopathology, 2018
The first clinical trials of the safety and efficacy of interferon-alpha2 (IFN-alpha2) were performed about 30 years ago. Since then, several single-arm studies have convincingly demonstrated that IFN-alpha2 is a highly potent anti-cancer agent in ...
H. Hasselbalch, M. Holmström
semanticscholar   +1 more source

Coexistence of chronic lymphocytic leukemia and polycythemia vera: a case report and review of the literature

Annals of Saudi Medicine, 2016
Polycythemia vera is a Philadelphia chromosome-negative myeloproliferative neoplasm. Chronic lymphocytic leukemia is a monoclonal expansion of a CD5+ CD19+ B lymphocytes.
Serdal Korkmaz, Sinan Kulakoglu, Hasan Gorkem, Bilal Aygun, Ali Cetinkaya   +4 more
doaj   +1 more source

EE236 Hospital Incidence and Medical Costs of Polycythemia Vera in Spain: A Retrospective Database Analysis [PDF]

, 2022
Josep Darbà, M Ascanio, A Marsà
openalex   +1 more source

Updates in the management of polycythemia vera and essential thrombocythemia

Therapeutic Advances in Hematology, 2019
Polycythemia vera (PV) and essential thrombocythemia (ET) are both classic, relatively indolent, chronic Philadelphia-chromosome-negative (Ph−) myeloproliferative neoplasms (MPNs) characterized by elevated blood counts, thrombotic as well as hemorrhagic ...
P. Bose, S. Verstovsek
semanticscholar   +1 more source

Targeted deep sequencing in polycythemia vera and essential thrombocythemia.

Blood Advances, 2016
Polycythemia vera (PV) is characterized by JAK2 and essential thrombocythemia (ET) by JAK2, calreticulin (CALR), and myeloproliferative leukemia virus oncogene (MPL) mutations; we describe the occurrence and prognostic relevance of DNA sequence variants ...
A. Tefferi, T. Lasho, P. Guglielmelli, C. Finke, G. Rotunno, Y. Elala, Annalisa Pacilli, C. Hanson, A. Pancrazzi, R. Ketterling, C. Mannarelli, D. Barraco, Tiziana Fanelli, A. Pardanani, N. Gangat, A. Vannucchi   +15 more
semanticscholar   +1 more source

Superior Vena Cava Syndrome in a Patient with Polycytemia Vera: Diagnosis and Treatment

Cardiology Research and Practice, 2010
Polycythemia vera is a myeloproliferative disorder characterized by thrombotic complications both in the arterial and venous systems. We report the case of a 55-year-old patient affected by polycythemia vera, presenting with acute superior vena cava ...
Salvatore Lentini, Mario Barone, Filippo Benedetto, Francesco Spinelli   +3 more
doaj   +1 more source

Pegylated Interferon Alpha-2b in Patients With Polycythemia Vera and Essential Thrombocythemia in the Real World [PDF]

, 2021
Yingxin Sun, Yifeng Cai, Jiannong Cen, Mingqing Zhu, Jinlan Pan, Qian Wang, Depei Wu, Suning Chen   +7 more
openalex   +1 more source

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo

Blood Cancer Journal, 2018
Polycythemia vera is characterized by the acquisition of the JAK2V617F mutation. Recommended treatments include hydroxyurea and interferon-alpha. Several groups have reported a reduction in the JAK2 mutant allele burden in interferon-treated patients ...
E. Verger, J. Soret-Dulphy, N. Maslah, L. Roy, J. Rey, Z. Ghrieb, R. Kralovics, H. Gisslinger, B. Grohmann-Izay, C. Klade, C. Chomienne, S. Giraudier, B. Cassinat, J. Kiladjian   +13 more
semanticscholar   +1 more source

Impending anterior ischemic optic neuropathy with elements of retinal vein occlusion in a patient on interferon for polycythemia vera

Clinical Ophthalmology, 2012
Kelly S Rue, Louis K Hirsch, Alfredo A SadunDepartment of Neuro-Ophthalmology, Doheny Eye Institute and Keck School of Medicine, University of Southern California, Los Angeles, CA, USAAbstract: We describe the course and likely pathophysiology of ...
Rue KS, Hirsch LK, Sadun AA
doaj  

Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study)

Haematologica, 2018
The purpose of this study was to identify the incidence, causes and impact of non-adherence to oral and subcutaneous chronic treatments for patients with polycythemia vera or essential thrombocythemia.
Ronan Le Calloch, Karine Lacut, Christelle Le Gall-Ianotto, Emmanuel Nowak, Morgane Abiven, Adrian Tempescul, Florence Dalbies, Jean-Richard Eveillard, Valérie Ugo, Stéphane Giraudier, Gaëlle Guillerm, Eric Lippert, Christian Berthou, Jean-Christophe Ianotto   +13 more
doaj   +1 more source